Published in Vaccine Weekly, July 13th, 2011
"This, however, poses a risk for an inflammatory and/or autoimmune response against A beta-peptides in the brain. To overcome such risks we wanted to identify the shortest C-terminal A beta-peptide that would induce antibodies selectively recognizing the C-terminal end...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.